Literature DB >> 25634607

The route to personalized medicine in bladder cancer: where do we stand?

Francesco Massari1, Chiara Ciccarese, Matteo Santoni, Matteo Brunelli, Alessandro Conti, Alessandra Modena, Rodolfo Montironi, Daniele Santini, Liang Cheng, Guido Martignoni, Stefano Cascinu, Giampaolo Tortora.   

Abstract

Recent advances in molecular biology and drug design have described novel targets in bladder cancer. EGFR, fibroblast growth factor receptor (FGFR), VEGFR, phosphoinositide 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, PD-1, cyclooxygenase 2 (COX-2), Aurora kinase A, and miRNA are just examples of these opening frontiers. In addition, epithelial to mesenchymal transition (EMT) and cancer stem cells (CSCs) are promising candidates for future therapeutic approaches. Novel agents, combination, and sequences are emerging from the 747 clinical studies presently in course in bladder cancer to optimize patient outcomes. This report describes the emerging targets and provides an update on ongoing phase I, II, and III trials and preliminary results on targeted agents, used alone, in sequences, or in combination for patients with bladder cancer.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25634607     DOI： 10.1007/s11523-015-0357-x

Source DB:  PubMed          Journal:  Target Oncol        ISSN： 1776-2596            Impact factor:   4.493


  115 in total

Review 1.  Biomarkers in bladder cancer: translational and clinical implications.

Authors:  Liang Cheng; Darrell D Davison; Julia Adams; Antonio Lopez-Beltran; Lisha Wang; Rodolfo Montironi; Shaobo Zhang
Journal:  Crit Rev Oncol Hematol       Date:  2013-08-29       Impact factor: 6.312

Review 2.  Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype?

Authors:  Héctor Peinado; David Olmeda; Amparo Cano
Journal:  Nat Rev Cancer       Date:  2007-05-17       Impact factor: 60.716

3.  Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours.

Authors:  Achim Fleischmann; Diana Rotzer; Roland Seiler; Urs E Studer; George N Thalmann
Journal:  Eur Urol       Date:  2011-05-25       Impact factor: 20.096

4.  Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer.

Authors:  J P Crew; T O'Brien; M Bradburn; S Fuggle; R Bicknell; D Cranston; A L Harris
Journal:  Cancer Res       Date:  1997-12-01       Impact factor: 12.701

5.  Distinct microRNA alterations characterize high- and low-grade bladder cancer.

Authors:  James W F Catto; Saiful Miah; Helen C Owen; Helen Bryant; Katie Myers; Ewa Dudziec; Stéphane Larré; Marta Milo; Ishtiaq Rehman; Derek J Rosario; Erica Di Martino; Margaret A Knowles; Mark Meuth; Adrian L Harris; Freddie C Hamdy
Journal:  Cancer Res       Date:  2009-10-20       Impact factor: 12.701

6.  Raf1, Aurora-A/STK15 and E-cadherin biomarkers expression in patients with pTa/pT1 urothelial bladder carcinoma; a retrospective TMA study of 246 patients with long-term follow-up.

Authors:  P Mhawech-Fauceglia; G Fischer; A Beck; R T Cheney; F R Herrmann
Journal:  Eur J Surg Oncol       Date:  2006-03-06       Impact factor: 4.424

7.  Prognostic value of amplification of c-erb-B2 in bladder carcinoma.

Authors:  U Lönn; S Lönn; S Friberg; B Nilsson; C Silfverswärd; B Stenkvist
Journal:  Clin Cancer Res       Date:  1995-10       Impact factor: 12.531

8.  Pazopanib and sunitinib trigger autophagic and non-autophagic death of bladder tumour cells.

Authors:  M Santoni; C Amantini; M B Morelli; S Liberati; V Farfariello; M Nabissi; L Bonfili; A M Eleuteri; M Mozzicafreddo; L Burattini; R Berardi; S Cascinu; G Santoni
Journal:  Br J Cancer       Date:  2013-07-25       Impact factor: 7.640

9.  FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer.

Authors:  D C Tomlinson; O Baldo; P Harnden; M A Knowles
Journal:  J Pathol       Date:  2007-09       Impact factor: 7.996

10.  Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erbB-2, p53) expression and long-term prognosis.

Authors:  P Lipponen; M Eskelinen
Journal:  Br J Cancer       Date:  1994-06       Impact factor: 7.640
View more
  8 in total

Review 1.  The importance of personalized medicine in urological cancers.

Authors:  Fatemeh Khatami; Mandana Hassanzad; Shekoufeh Nikfar; Fateme Guitynavard; Samira Karimaee; Saeyed Saeed Tamehri Zadeh; Keykavos Gholami; AhmadReza Rezaeian; Seyed Ariana Feiz-Abadi; Fatemeh Jahanshahi; Seyed Mohammad Kazem Aghamir
Journal:  J Diabetes Metab Disord       Date:  2021-06-29

2.  Lentiviral interferon: A novel method for gene therapy in bladder cancer.

Authors:  Sharada Mokkapati; Vikram M Narayan; Ganiraju C Manyam; Amy H Lim; Jonathan J Duplisea; Andrea Kokorovic; Tanner S Miest; Anirban P Mitra; Devin Plote; Selvalakshmi Selvaraj Anand; Michael J Metcalfe; Kenneth Dunner; Burles A Johnson; Bogdan A Czerniak; Tiina Nieminen; Tommi Heikura; Seppo Yla-Herttuala; Nigel R Parker; Kimberley S Schluns; David J McConkey; Colin P Dinney
Journal:  Mol Ther Oncolytics       Date:  2022-06-10       Impact factor: 6.311

3.  Chronic inflammation in urothelial bladder cancer.

Authors:  Gabriella Nesi; Stefania Nobili; Tommaso Cai; Saverio Caini; Raffaella Santi
Journal:  Virchows Arch       Date:  2015-08-12       Impact factor: 4.064

Review 4.  Bladder Cancer Stem-Like Cells: Their Origin and Therapeutic Perspectives.

Authors:  Tomokazu Ohishi; Fumitaka Koga; Toshiro Migita
Journal:  Int J Mol Sci       Date:  2015-12-29       Impact factor: 5.923

Review 5.  The New Age of -omics in Urothelial Cancer - Re-wording Its Diagnosis and Treatment.

Authors:  Theodora Katsila; Michalis Liontos; George P Patrinos; Aristotelis Bamias; Dimitrios Kardamakis
Journal:  EBioMedicine       Date:  2018-02-02       Impact factor: 8.143

Review 6.  Key Role of Obesity in Genitourinary Tumors with Emphasis on Urothelial and Prostate Cancers.

Authors:  Matteo Santoni; Alessia Cimadamore; Francesco Massari; Francesco Piva; Gaetano Aurilio; Angelo Martignetti; Marina Scarpelli; Vincenzo Di Nunno; Lidia Gatto; Nicola Battelli; Liang Cheng; Antonio Lopez-Beltran; Rodolfo Montironi
Journal:  Cancers (Basel)       Date:  2019-08-22       Impact factor: 6.639

7.  Abnormal Protein Glycosylation and Activated PI3K/Akt/mTOR Pathway: Role in Bladder Cancer Prognosis and Targeted Therapeutics.

Authors:  Céu Costa; Sofia Pereira; Luís Lima; Andreia Peixoto; Elisabete Fernandes; Diogo Neves; Manuel Neves; Cristiana Gaiteiro; Ana Tavares; Rui M Gil da Costa; Ricardo Cruz; Teresina Amaro; Paula A Oliveira; José Alexandre Ferreira; Lúcio L Santos
Journal:  PLoS One       Date:  2015-11-16       Impact factor: 3.240

Review 8.  Stem-Like Signature Predicting Disease Progression in Early Stage Bladder Cancer. The Role of E2F3 and SOX4.

Authors:  Joaquim Bellmunt
Journal:  Biomedicines       Date:  2018-08-02
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.